Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates.

ABSTRACT:

Context

Several phase III randomized controlled trials (RCTs) have shown the importance of perioperative systemic therapy, especially for the efficacy of immune checkpoint inhibitors (ICIs) in both neoadjuvant and adjuvant settings for muscle-invasive bladder cancer (MIBC).

Objective

To synthesize the growing evidence on the efficacy and safety of systemic therapies for MIBC utilizing the data from RCTs.

Evidence acquisition

Three databases and ClinicalTrials.gov were searched in October 2024 for eligible RCTs evaluating oncologic outcomes in MIBC patients treated with systemic therapy. We evaluated pathological complete response (pCR), disease-free survival (DFS), progression-free survival (PFS), event-free survival (EFS), overall survival (OS), and adverse events (A

SUBMITTER: Yanagisawa T 

PROVIDER: S-EPMC12035237 | biostudies-literature | 2025 Apr-Jun

REPOSITORIES: biostudies-literature